Recently, Epic Sciences Inc, which is a company that develops better and personalized treatment for cancer patients, announced that it will present detailed findings on its new proprietary technology for the diagnosis of cancer cells, particularly for breast cancer tumors.
More specifically, the newly developed liquid biopsy test will help in the detection of circulating tumor cells (CTCs). The test will profile the cells on the basis of morphological features, protein marker expression, and genomic alterations.
The data and further information on the biopsy test will be presented by Epic Sciences in the 2019 San Antonio Breast Cancer Symposium which is planned to be held from ten to fourteen December in the city of San Antonio in Texas.
The breast cancer symposium is designed specifically for presenting cutting edge technology for diagnosis, experimental, therapy, prevention, biology, and etiology, of breast cancer as well as premalignant cancers for physicians, clinicians, and researchers from around the world. The symposium will provide a platform for interaction and gaining knowledge and education for breast cancer.
The technology used in Epic Sciences profiles all circulating tumor cells in a blood sample in order to predict and observe the activities and responses of those cells while also looking at the potential development of drug or therapy resistance.
This technology by the company was first used as a diagnostic test for metastatic castration-resistant prostate cancer. Currently, the test is marketed with the name Oncotype DX AR-V7 Nucleus Detect™ test.
Now, Epic Sciences is using the same technology for analyzing and the identifications of circulating tumor cells for improvements in the treatment for breast cancer. The chief medical officer of Epic Sciences, Rick Wenstrup states that prostate cancer and breast cancer have a number of similarities on a biological basis.
He adds that the ability to detect subtypes and cancer cell clones can help in significant developments for aggressive breast cancer cells and controlling their division. According to the statistics, around twelve percent of the women, which is approximately one in eight-woman, will develop invasive breast cancer at least once in her lifetime.
There were around 268,600 new cases of invasive breast cancer in 2019 alone along with 62,930 more cases of in-situ or non-invasive breast cancer in the United States. On the other hand, men have a comparatively lower risk of breast cancer. About one in eight hundred and eighty-three men will develop the disease. However, there were also 2,670 cases of breast cancer in men.
Additionally, an estimated 41,760 women have lost their lives to breast cancer. After the advancements in the treatment and different options for the health condition, the number of deaths resulting from it decreased but breast cancer still remains to be the most commonly diagnosed cancer in women. Thirty percent of the newly diagnosed cases are likely to be breast cancer.
Therefore, more advanced technology for the treatment and accurate detection of breast cancer in both women and men is needed. The new data obtained by the liquid biopsy test by Epic Sciences is likely to contribute significantly to the medical literature present on the topic.